Q2 2021 Results - Reimagining Medicine

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations GP2411 - Biosimilar denosumab Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT03974100 (CGP24112301) Osteoporosis Phase 3 522 Percent change from baseline (%CfB) in lumbar spine Bone Mineral Density GP2411 60 mg/mL subcutaneous injection every 6 months ProliaⓇ 60 mg/mL subcutaneous injection every 6 months Postmenopausal women with osteoporosis Target Patients Read-out Milesstone(s) 2022 Publication Study data publications expected for 2024 and beyond. The overall study design will be published at WCO and ECTS congresses 2020. 131 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation